The EU has given Gilead the green light to market its twice-yearly pre-exposure prophylaxis (PrEP) product lenacapavir, which ...

Roche's Genentech unit has started work on a $700 million manufacturing facility in North Carolina, part of a promised $50 ...

The 18th PFS & Injectable Drug Devices Europe Conference returns to London next January, setting the tone for 2026 with a ...

That’s why this year’s Antifibrotic Drug Development Summit is THE place to be this November. Learn from the industry’s ...

Anti-amyloid antibody Leqembi (lecanemab) made its EU debut in Austria yesterday and will be introduced in Germany on Monday ...

It turns out that AbbVie is only interested in buying Gilgamesh's lead drug programme, a psychedelic candidate for major ...

Despite being a rare disease impacting less than a million people worldwide, gMG treatment is an increasingly crowded market, ...

Nucleus RadioPharma, the radiopharmaceutical-focused contract developing and manufacturing organisation founded by Eclipse ...

A new study published in the Nature journal of Mental Health Research shows powerful real-world evidence for the efficacy of ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Suzanne Aitken, SVP of managed access at Clinigen, ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

Washington DC-based Vanda was sent a complete response letter (CRL) from the FDA in 2019, rejecting Hetlioz (tasimelteon) for ...